Zydelig

Chemical Nameidelalisib
Dosage FormTablet (oral; 100 mg, 150 mg)
Drug ClassKinase Inhibitors
SystemBlood
CompanyGilead Sciences
Approval Year2014

Indication

  • For the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
  • For the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
  • For the treatment of patients with relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.
Last updated on 7/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zydelig (idelalisib) Prescribing Information.2022Gilead Sciences, Inc., Foster City, CA